Updated: Acadia wins first FDA approval for Rett syndrome drug

Paul Schloesser

Associate Editor

Drew Armstrong

Executive Editor

The FDA on Friday approved Acadia Pharmaceuticals’ treatment for Rett syndrome, a rare neurodevelopmental disorder, which will be sold under the brand name Daybue …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: Acadia wins first FDA approval for Rett syndrome drug

Paul Schloesser

Associate Editor

Drew Armstrong

Executive Editor

Sign up to read this article for free.

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Up­dat­ed: Aca­dia wins first FDA ap­proval for Rett syn­drome drug

Associate Editor

Executive Editor

Sign up to read this article for free.

Updated: Acadia wins first FDA approval for Rett syndrome drug